14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
Recent New York legislation in reaction to the #MeToo movement has sought to limit or foreclose arbi...
Read More >
On May 15, 2019, the President of Uzbekistan signed a decree making the entire territory of Navoi re...
Read More >
The Family and Medical Leave Act (FMLA) doesn’t cover an employee’s leave to care for the healthy ...
Read More >
Chicago recently joined a growing trend when City Council approved one of the broadest predictive sc...
Read More >
This week in our blog series on best practices in administering benefit claims, we discuss the impor...
Read More >
The holiday cheer keeps coming from the National Labor Relations Board (NLRB) with the release of th...
Read More >